Moderna Lifts Its Estimate for 2021 Coronavirus Vaccine Production by 20%

If all goes according to its revised plan, Moderna (NASDAQ:MRNA) will have far more doses of its coronavirus vaccine on the market than formerly anticipated. The company announced Monday that it is lifting its base-case estimate for global production of mRNA-1273 in 2021 to 600 million doses from the previous forecast of 500 million.